secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001193125-25-062629
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio reports Q4/FY2024 results, cash $212.5M through 2027; launches $22.35M ATM offering
--------------------------------------------------------------------------------

- Entered ATM equity offering of up to $22.35M via Oppenheimer; 3% commission; proceeds to support pipeline.
- Cash, equivalents and marketable securities $212.5M at year-end; expected to fund operations through 2027.
- Net loss $73.9M for FY2024 includes $51.7M in-process R&D from Tenet acquisition; Q4 net loss $8.4M.
- FDA cleared Phase 2 trial for budoprutug in pMN and Phase 1b/2a in ITP; dosing starts H1/H2 2025.
- In-licensed CLYM116 (anti-APRIL) for IgAN; IND-enabling; preclinical data H2 2025; new CBO Perrin Wilson.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525062629/0001193125-25-062629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525062629/d943630d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-062629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer